Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance
Abstract Background The risk of delayed autoimmunity occurring months or years after discontinuation of immunotherapy is frequently asserted in the literature. However, specific cases were rarely described until 2018, when a wave of reports surfaced. With expanding I-O indications in the adjuvant/ne...
Main Authors: | Marcus A. Couey, R. Bryan Bell, Ashish A. Patel, Meghan C. Romba, Marka R. Crittenden, Brendan D. Curti, Walter J. Urba, Rom S. Leidner |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-019-0645-6 |
Similar Items
-
Harnessing NK Cell Checkpoint-Modulating Immunotherapies
by: Sachin Kumar Singh Chauhan, et al.
Published: (2020-07-01) -
Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity
by: Cao, L., et al.
Published: (2022) -
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
by: Stefanie R. Mullins, et al.
Published: (2019-09-01) -
Cancer patients’ experiences with immune checkpoint modulators: A qualitative study
by: Kari Ala‐Leppilampi, et al.
Published: (2020-05-01) -
Immune Checkpoints as Therapeutic Targets in Autoimmunity
by: Christopher Paluch, et al.
Published: (2018-10-01)